Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- GSK Japan Ups Recall Level for Zantac to “Class I”
October 10, 2019
- Sosei Bags US$3 Million from Genentech on Nomination of New GPCR Disease Target
October 10, 2019
- Mitsubishi Tanabe Gains Japan, Asian Rights for Viela Bio's Inebilizumab
October 10, 2019
- Meiji to Strengthen Contract Manufacturing, Aims to Produce 3 Billion Tablets Annually for Japan Market
October 10, 2019
- Bayer, RIKEN Innovation Tie Up on Drug Discovery
October 9, 2019
- AbbVie Japan Set to Join Oncology Fray with CLL Drug, Accelerating FIH Trial Entry
October 9, 2019
- Toray Launches Recall of Careload for Possible Placebo Mix-Up
October 9, 2019
- Gilead Files JAK Inhibitor Filgotinib in Japan
October 9, 2019
- Yakult to Promote Servier’s Anticancer Agent Liposomal Irinotecan in Japan
October 9, 2019
- Wholesalers Working Out Systems to Comply with Promotion Guidelines, Show Mixed Approaches to External Oversight
October 8, 2019
- Sanofi to Shed 200 Jobs in Japan
October 8, 2019
- Chris Hartz to Helm Amicus Japan
October 8, 2019
- Japan Ethical Drug Sales Up 3.0% in August: Crecon
October 8, 2019
- Keytruda Filed for Gastric Cancer in Japan
October 7, 2019
- Keytruda Remains Japan’s Top-Selling Drug in September: Encise
October 7, 2019
- Shionogi, M3 Establish New JV to Provide Disease Solutions by Integrating Physical and Digital Assets
October 7, 2019
- Trader Mitsui’s Iwai Picked for Top Job at Fuji Pharma
October 7, 2019
- All 11 Manufacturers Pull Ranitidine from Shelves, “Class I” Recalls for 9 Firms
October 4, 2019
- Japan IP High Court Favors Chugai in Hemlibra Patent Suit
October 4, 2019
- Novel Antibiotic Cefiderocol Meets Primary Endpoint in Global PIII: Shionogi
October 4, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…